Learning Objectives:

  1. Revew the current state of the thoracic program, including initiatives.

2.  Discuss COSINR, trail of ipilimumab, nivolumab, SBRT for        untreated Stage IV NSCL

3. Present DARES, a trial of carboplatin, etoposide, durvalumab, and SBRT for extensive stage small cell.

Session date: 
Monday, March 8, 2021 - 12:00pm to 1:00pm
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Christine M. Bestvina, MD